ATS' DERMAGRAFT FOR DIABETIC ULCERS NEEDS RANDOMIZED POSTMARKET EFFICACY STUDY, PANEL SAYS JAN. 29; SKIN GRAFT APPROVAL SUPPORTED IN 7-2 VOTE
This article was originally published in The Gray Sheet
Executive Summary
Advanced Tissue Sciences' Dermagraft premarket approval application to use the bioengineered human skin graft in healing diabetic foot ulcers is approvable with two conditions, FDA's General and Plastic Surgery Devices panel recommended by a 7-2 vote at its Jan. 29 meeting in Gaithersburg, Maryland.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.